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SUMMARY  
The aim of this study was to estimate the prevalence of hepatitis B exposure in the 
population of the Republic of Ireland, by measuring the prevalence of hepatitis B anti-
core antibody in oral fluid collected by postal survey.  
A random multi-stage stratified sample of Irish households was obtained, using the 
Irish electoral register as the sampling frame. A total of 962 households were selected, 
and a household response rate of 60.4% was achieved. Oral fluid specimens totalling 
1714 were tested for antibody to hepatitis B core antigen (anti-HBc), using an 
Immune Capture Enzyme Immuno-Assay. Five specimens (0.29%) were found to 
contain anti-HBc. Adjusting for study design, the estimated anti-HBc prevalence in 
the Republic of Ireland is 0.51%.  
 
This study demonstrates that self-collection of oral fluid samples is acceptable to the 
public, and based upon the data generated, that the Republic of Ireland has a low 
prevalence of hepatitis B infection.  
 
INTRODUCTION  
Hepatitis B virus (HBV) is one of the world’s most common and serious infectious 
diseases. It is estimated that about two billion people who are alive today have at 
some time been infected with HBV. About 350 million people are chronic carriers of 
HBV [1]. This represents a very large reservoir of virus.  
 
Approximately 160000 cases of acute HBV infection are reported each year in the 
WHO European region [2]. Owing to under-reporting and the fact that at least 50% of 
HBV infections are asymptomatic, the World Health Organisation has extrapolated 
from these figures and estimates that one million people are infected in the WHO 
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European region annually. Of these, approximately 90000 will become chronically 
infected and about 22000 will die from cirrhosis and liver cancer [2]:  
 
In 1991, the World Health Organisation (WHO) called on all countries to introduce 
universal hepatitis B immunization by 1997 [3]. In Western Europe, a number of 
countries have instituted national policies to immunize infants or adolescents against 
HBV. These include Belgium, France, Germany, Italy and Spain. However, Ireland, 
the United Kingdom, The Netherlands and the Scandinavian countries have not yet 
instituted national immunization programmes [4], having policies of targeting ‘ at 
risk’ populations for immunization.  
 
The prevalence of HBV infection in the general population of the Republic of Ireland 
is not known. HBV is a notifiable disease, and the number of notifications per annum 
between 1989 and 1997 ranged from 10 to 30, but increased sharply in 1998 to 155 
[5], in a national population of 3.66 million. However, the extent of under-reporting 
or duplication of notifications of HBV infection is unknown. Testing of new blood 
donors has shown HBsAg positive rates of approximately 0.026% between 1993 and 
1997 [5], whilst testing among the antenatal population in two Irish hospitals has 
show HBsAg positive rates of approximately 0.03-0.22% between 1995 and 1998 [5].  
 
The aim of this study was to estimate the prevalence of HBV infection in the 
population of the Republic of Ireland. This was to be achieved by measuring the 
prevalence of anti-core antibody (anti-HBc), a marker of current or past HBV 
infection [6], in a representative sample of the Irish population using self-collected 
oral fluid samples.  
 
METHODS  
In the absence of a population register, the sampling frame used was the Register of 
Electors for Irish parliamentary elections. This register consists of 3444 local listings 
of the names and addresses of adults over the age of 18 who are registered to vote. 
These local divisions of electors are known as District Electoral Divisions (DEDs). 
The electoral register was last updated in April 1998.  
 
The objective was to choose a representative sample from the 3444 DEDs that would 
reflect the Irish population. The 3444 DEDs were first stratified into urban and rural 
strata. These were then sub-stratified into three different socio-economic strata (high, 
middle and low socio-economic categories), using a classification system developed 
by the Small Area Health Research Unit [7]. Thus, there were six different strata of 
DED type. Three DEDs were chosen at random from each of the six strata, giving a 
total of 18 DEDs nationally.  
 
Sample size calculations were performed using the Epi-Info software package [8]. 
Our experimental hypothesis was that the prevalence of anti-HBc in the Irish 
population was 1±0.5%. This was based on extrapolating from published data on 
hepatitis B positivity in blood donors and antenatal women [5]. A net household 
response rate of 50% was expected and a design effect of two was assumed. It was 
assumed that approximately 10% of persons listed at a given address would have died 
or moved elsewhere, based on the results of a national health promotion study that 
also used the electoral register [9]. Since the average Irish household size is 3.2 
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persons [8], a sample of 900 households was required from 18 DEDs. Households 
were selected at random from the 18 DED listings.  
However, in some DEDs, a larger than expected number of persons listed had either 
moved elsewhere or died. A small additional top-up sample was required in 10 of the 
18 DEDs, where in 5 or more households, the individual contacted had died or 
moved. Thus the final number of households sampled was 962.  
 
Sample collection took place between November 1998 and January 1999. Targeted 
households received an initial letter outlining the aims of the study. They then 
received a package containing a letter with easy-to-follow instructions, six foam 
swabs to collect the oral fluid and a reply postcard. The household member to whom 
the letter was addressed was asked to collect an individual sample from each 
household member, and to mark the age and sex of the individual on the outside of the 
transport tube using specially supplied labels.  
 
Samples were returned to a free postal address in University College Dublin. 
Respondents were asked to return the postcard with their name and address to a 
separate free postal address in the North Eastern Health Board, where the study was 
co-ordinated. This postcard was to identify those individuals who had returned 
specimens so that they would not be contacted again. Respondents were asked to 
detail on this postcard whether all family members took part, or whether some 
individuals were missed.  
 
Non-respondents received two reminder letters, and if possible, were also telephoned. 
A telephone helpline number was included in all mailshots. A press release describing 
the study was circulated to the national and local press.  
 
The age, sex and area post code (DED) of origin of the oral swabs received were 
recorded in a database. The contents of the foam swab were eluted in Phosphate-
Buffered Solution Tween (PBST) and stored at -20 °C in a Starstedt tube until testing. 
To determine the validity of a sample prior to anti-HBc investigation, an ‘in-house’ 
IgG quantification assay was used. Those with IgG concentrations in excess of 0.313 
mg/1, a level established to provide an accurate result, were then tested for anti-HBc 
antibodies.  
 
Two different anti-HBc assays were used, both of which were based on the immune 
capture technique. The first assay was a commercially available anti-HBc combined 
IgG/IgM test employing a peroxidase conjugated HBc antigen (Murex ICE™HBc, 
Murex Biotech Limited, Dartford, Kent, England). The second assay was an IgG-
specific test, employing an alkaline phosphatase conjugated HBc antigen, which was 
developed and validated in the Virus Reference Laboratory, University College 
Dublin.  
 
RESULTS  
A total of 962 households were asked to participate. In 135 households, the person to 
whom the letter was written had changed address, whilst in 15 households the person 
had died. Sixty per cent (491/812) returned 1738 samples, an average of 3.6 samples 
per household. The response rate varied across the six DED strata, with the lowest 
response rate seen in the urban low socio-economic category (48%), and the highest 
response rate seen in the urban high socio-economic category (65%). The age and sex 
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profile of the respondent population closely matched the age and sex profile of the 
Irish population (Table 1).  
 
Of the 491 households that returned samples, 447 (93%) also returned the, reply 
postcard. Of these, 84% indicated that everyone in their household supplied 
specimens and 16% indicated that one or more persons in their household had not 
participated. This incomplete household response rate of 16% was fairly uniform 
across the six different DED strata (range 13-19%).  
 
A total of 1714 (98.6%) of the 1738 swab eluates were suitable for testing. Eleven 
(0.64%) were repeat reactive on the ICE™HBc assay, and of these, five were 
confirmed anti-HBc positive using the confirmatory assays. The remaining six were 
unconfirmed screen reactives, and classified as negative. Also 1703 (99.36%) tested 
negative for anti-HBc. Thus, the crude prevalence of anti-HBc in the study population 
was 0.29% (95% CI: 0.04-0.55%).  
 
The age, sex and DED strata of these five confirmed positives are shown in Table 2. 
The crude prevalence of anti-HBc in the study population (0.29%) was adjusted to 
calculate an estimated Irish population prevalence for HBV exposure, taking account 
of the multistage stratified cluster design used. This was achieved using the svy 
package from Stata Corporation (Stata Corporation, 1997).  
 
The adjustment for stratification and clustering had little effect on the estimated 
prevalence figure. However, the adjustment for sample weighting had a larger effect, 
With the estimated mean prevalence almost doubling to 0.51% (95% CI: 0-1.18%).  
 
Table 1. Comparison of study population and Irish population by age and sex  
Age (years)  .% in study population  % in Irish population  
<5  6.3  6.9  
5-14  15.3  16.8  
15-24  16.9  17..5  
25-44  29.7  28.0  
45-64  22.3  19.4  
65+  9.5  11.4  
Total  100  100  
Sex  
Male  48.6  49.6  
Female  51.4  50.4  
Total  100  100  
 
Table 2. Stratum type/age/sex of confirmed HBV positives  
Stratum  Age  Sex  
Rural middle socio-economic  40  Male  
Rural middle socio-economic  52  Male  
Urban middle socio-economic  58  Female  
Urban low socio-economic  34  Male  
Urban low socio-economic  70  Female  
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DISCUSSION  
From a 30-year review of the Medline database, this is the first time that a national 
epidemiological study using oral fluid collection by postal survey has been published. 
A high response rate (60.4%) was achieved. Virtually all of the specimens (98.6%) 
provided were suitable for anti-HBc testing, indicating that this method of sample 
collection is feasible.  
 
This study estimated that the prevalence of HBV exposure in the population of the 
Republic of Ireland was 0.51%. Thus, Ireland is classified as a low prevalence country 
for HBV infection [6]. 
 
The estimated anti-HBc prevalence in the Irish population of 0.51% had nominal 95% 
confidence intervals. This was because the study population prevalence of anti-HBc 
found in this study (0.29%) was lower than the estimated study population prevalence 
anticipated in the sample size calculations (0.5-1.5%).  
 
There is no information on non-responding households. It was considered that 
contacting non-respondents after four mail shots and a telephone call would be 
excessive. No information on the presence of hepatitis B risk factors or past history of 
jaundice was collected, as we considered that asking for this additional information 
would adversely effect response rates. Thus, it is possible that high-risk individuals 
were not included in the study, either because they were not on the electoral register 
in the first place, or because they did not take part in the study.  
 
The estimated Irish population anti-HBc prevalence of 0.51% was almost twice the 
crude study prevalence of 0.29%, due to the effect of sample weighting. This was 
because in 2 of the 6 strata, the DEDs selected had a smaller than expected 
population. Critically, 4 out of the 5 positives occurred in these 2 strata (urban low 
socio-economic stratum, rural middle socio-economic stratum). This under-
representation was due to random sampling bias and not non-response bias.  
 
In 1991, the WHO called for all countries to add hepatitis B vaccine to their national 
immunization programmes [3]. By 1999, most countries in Western Europe had 
introduced universal infant and/or adolescent vaccination programmes [4].  
Some authors have argued that in the low endemicity countries of North Western 
Europe, this global strategy for hepatitis B is inappropriate [10]. Ireland, the United 
Kingdom, The Netherlands and the Scandinavian countries have not implemented 
universal vaccination programmes [4]. The National Immunisation Committee in 
Ireland has recommended a policy of selective rather than universal immunization [5].  
 
A variety of arguments are advanced by those who advocate selective rather than 
universal immunization in low endemicity countries. The introduction of an additional 
infant vaccination may affect the uptake of other childhood vaccinations [11]. 
Universal infant immunization does not prevent perinatal transmission [11]. The 
introduction of adolescent immunization may be hampered by asking parents to 
accept an immunization against an infection that is spread sexually and through 
intravenous drug use [11]. No convincing economic case has been made to justify the 
cost of HBV immunization in low endemicity countries [12]. Thus, within Europe, the 
debate on universal versus selective immunization remains ongoing.  
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Based upon this study, the Republic of Ireland currently has a very low rate of HBV 
infection in the general population. This study has also found that oral fluid collection 
by postal survey is a useful tool for epidemiological surveys. The public are willing to 
provide self-collected oral fluid samples for virological investigations, provided the 
anonymous and unlinked nature of the study is emphasized.  
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